NEW YORK (GenomeWeb News) – Foundation Medicine reported after the close of the market Wednesday that its first quarter revenues rose 121 percent from the first quarter of 2013 and 19 percent sequentially, driven by sales of its FoundationOne and FoundationOne Heme cancer tests.

The Cambridge, Mass.-based cancer genomic analysis firm reported total revenues of $11.5 million for the three months ended March 31, up from $5.2 million in Q1 2013 and $9.7 million in Q4 2013. It beat the consensus Wall Street estimate of $11.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.